Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

About this update from Kyverna Therapeutics, Inc.

EMERYVILLE, Calif. , March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle , Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025 , at 3:00 p.m. ET . A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com . A replay of the webcast will be available on the website for 30 days following the conference. About Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase 2 trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. Kyverna is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for it to advance into late-stage development. Its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit  https://kyvernatx.com . Contact: Investors: [email protected]   Media: [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-present-at-the-leerink-partners-global-biopharma-conference-302390580.html SOURCE Kyverna Therapeutics

View stock analysis, news, and events for Kyverna Therapeutics, Inc.